Prognostic and therapeutic potential of STAT3: Opportunities and challenges in targeting HPV-mediated cervical carcinogenesis

Crit Rev Oncol Hematol. 2024 May:197:104346. doi: 10.1016/j.critrevonc.2024.104346. Epub 2024 Apr 10.

Abstract

Cervical cancer (CaCx) ranks as the fourth most prevalent cancer among women globally. Persistent infection of high-risk human papillomaviruses (HR-HPVs) is major etiological factor associated with CaCx. Signal Transducer and Activator of Transcription 3 (STAT3), a prominent member of the STAT family, has emerged as independent oncogenic driver. It is a target of many oncogenic viruses including HPV. How STAT3 influences HPV viral gene expression or gets affected by HPV is an area of active investigation. A better understanding of host-virus interaction will provide a prognostic and therapeutic window for CaCx control and management. In this comprehensive review, we delve into carcinogenic role of STAT3 in development of HPV-induced CaCx. With an emphasis on fascinating interplay between STAT3 and HPV genome, the review explores the diverse array of opportunities and challenges associated with this field to harness the prognostic and therapeutic potential of STAT3 in CaCx.

Keywords: Cervical cancer (CaCx); Human papillomavirus (HPV); Prognosis; Signal transducer and activator of transcription 3 (STAT3); Therapeutics.

Publication types

  • Review

MeSH terms

  • Carcinogenesis / genetics
  • Female
  • Humans
  • Papillomaviridae / genetics
  • Papillomavirus Infections* / complications
  • Papillomavirus Infections* / therapy
  • Papillomavirus Infections* / virology
  • Prognosis
  • STAT3 Transcription Factor* / genetics
  • STAT3 Transcription Factor* / metabolism
  • Uterine Cervical Neoplasms* / diagnosis
  • Uterine Cervical Neoplasms* / etiology
  • Uterine Cervical Neoplasms* / metabolism
  • Uterine Cervical Neoplasms* / therapy
  • Uterine Cervical Neoplasms* / virology

Substances

  • STAT3 Transcription Factor
  • STAT3 protein, human